factor VIII inhibitor bypassing activity at a glance
Medicine class
Plasma-derived activated prothrombin complex concentrate, also called a bypassing agent.
Administration
Slow intravenous infusion after reconstitution.
Specialist oversight
Initiated and monitored by a clinician experienced in coagulation disorders.
Product origin
Made from donated human plasma using donor screening and pathogen-reduction measures.
What is factor VIII inhibitor bypassing activity used for?
Licensed UK uses include:
Treatment and prevention of bleeding in haemophilia A with inhibitors.
Treatment of bleeding in haemophilia B with inhibitors.
Treatment and prevention of bleeding in people with acquired factor VIII inhibitors.
Prevention of bleeding around surgery in haemophilia A with inhibitors.
How does factor VIII inhibitor bypassing activity work?
It contains several clotting factors that support thrombin generation and clot formation despite factor VIII or IX being blocked by an inhibitor.
How to take factor VIII inhibitor bypassing activity
Use only as instructed by the haemophilia team. Mix the powder with the supplied water for injections using aseptic technique, then infuse it slowly into a vein.
Swirl gently rather than shaking and ensure the powder dissolves completely.
Do not use a cloudy solution or one containing deposits.
Prepare immediately before use and begin the infusion promptly.
Do not refrigerate the reconstituted solution or reuse opened containers.
Do not mix with other medicines in the same preparation.
Record the product name and batch number after each administration.
factor VIII inhibitor bypassing activity side effects
Common or expected effects
- Headache
- Dizziness
- Low blood pressure
- Rash
- Hypersensitivity reactions
- A positive hepatitis B surface-antibody test caused by passively transferred antibodies
Get urgent medical advice
- Severe allergic reaction, including facial or tongue swelling, wheezing, breathing difficulty or circulatory collapse
- Blood clots, including deep-vein thrombosis, pulmonary embolism, heart attack or stroke
- Disseminated intravascular coagulation
- Serious infusion reactions involving chest pain, breathing difficulty or major changes in pulse or blood pressure
factor VIII inhibitor bypassing activity in pregnancy
Evidence is limited, and pregnancy increases the risk of thrombosis and some clotting complications. Use only when clearly needed following specialist assessment, with careful monitoring.
factor VIII inhibitor bypassing activity while breastfeeding
Clinical data are insufficient. Transfer into milk is expected to be very low because the clotting factors are large proteins, but use requires individual specialist assessment, particularly because clotting risk is increased after birth.
factor VIII inhibitor bypassing activity interactions
The haemophilia team should review all haemostatic treatments because some combinations may increase clotting complications.
Systemic antifibrinolytics, including tranexamic acid and aminocaproic acid
Use close to this treatment may increase thromboembolic risk, so timing must be directed by a specialist.
Recombinant activated factor VII
Combined or sequential use may increase thromboembolic risk.
Emicizumab
Serious thrombotic microangiopathy and thrombotic complications have occurred with intensive combined exposure. Specialist assessment and close monitoring are required.
Common questions about factor VIII inhibitor bypassing activity
Answers are fully visible for fast scanning and source review.
Is it the same as factor VIII?
No. It is a mixture of clotting factors that generates thrombin through pathways that do not depend on factor VIII working normally.
Does it remove the inhibitor?
Its main purpose is to control or prevent bleeding by bypassing the inhibitor. Treatment intended to eradicate an inhibitor is planned separately by the specialist team.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.